Skip to search formSkip to main contentSkip to account menu

SU101

National Institutes of Health

Related topics

Related topics

9 relations

Broader (8)

Anti-Inflammatory Agents, Non-SteroidalAntiparasitic AgentsEnzyme InhibitorsGrowth Inhibitors
HWA 486

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The Liddy Shriver Sarcoma Initiative
Desmoplastic small round cell tumor (DSRCT) is an aggressive malignant neoplasm that occurs in adolescents and young adults. This… 
2004
2004
Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101
PurposeTo determine the maximum tolerated dose and the toxicity profile of the PDGF receptor pathway inhibitor SU101 in pediatric… 
2004
2004
Evaluation of Early Response to SU101 Target-based Therapy in Patients with Recurrent Supratentorial Malignant Gliomas Using FDG PET and Gd-DTPA MRI
Changes in [18F]-2-fluoro-2-deoxyglucose (FDG) uptake and gadopentetate dimeglumine (Gd-DTPA) enhancement before and after the… 
2002
2002
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
Review
2001
Review
2001
A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.
In a multi-institutional Phase II trial, we evaluated the efficacy of a platelet-derived growth factor receptor (PDGF-r… 
2000
2000
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
SU101 (leflunomide, N-[4-(trifluoromethyl)-phenyl] 5-methylisoxazole-4-carboxamide), an inhibitor of platelet-derived growth… 
Highly Cited
1999
Highly Cited
1999
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
PURPOSE To evaluate the clinical feasibility and pharmacologic behavior of the platelet-derived growth factor (PDGF) tyrosine… 
Review
1999
Review
1999
Implications for Src kinases in hematopoiesis: signal transduction therapeutics.
Signal transduction therapeutics is now the dominant theme of drug discovery, and its most immediate impact will be in cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)